Search

Displaying results 3091 - 3100 of 4437 in total
  1. Drug

    Alclometasone

    go.drugbank.com/drugs/DB00240
    Approved

    Alclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent.

  2. Drug

    Belatacept

    go.drugbank.com/drugs/DB06681
    ApprovedInvestigational

    It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011.

  3. Drug

    Adenosine 5'-phosphosulfate

    go.drugbank.com/drugs/DB03708
    Investigational

    The initial compound formed by the action of ATP sulfurylase on sulfate ions after sulfate uptake. Synonyms: adenosine sulfatophosphate; APS.

  4. Drug

    VaxSyn

    go.drugbank.com/drugs/DB17827
    Investigational

    VaxSyn HIV-1 is a recombinant form of the HIV envelope protein gp 160 developed by MicroGeneSys and the National Institute of Allergy and Infectious Diseases (NIAID).

  5. Drug

    ENTR-601-44

    go.drugbank.com/drugs/DB17836
    Investigational

    Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]

  6. Drug

    PAS-004

    go.drugbank.com/drugs/DB18611
    Investigational

    PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.

  7. Drug

    NV-18

    go.drugbank.com/drugs/DB05886
    Experimental

    Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma (cancer

  8. Drug

    Eperisone

    go.drugbank.com/drugs/DB08992
    Investigational

    It is not approved for use in the United States, but is available in other countries like India, South Korea, and Bangladesh.

    Products: MYONAL TABLET 50MG
  9. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer

  10. Drug

    Gentian violet cation

    go.drugbank.com/drugs/DB00406
    Approved

    A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.